Across four studies in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), approximately half of people receiving faricimab could be treated every four months in the first year Approximately three-quarters of people receiving faricimab could be treated every three months or longer in the first year Faricimab sho

Tecentriq in combination with Avastin provides the longest overall survival seen in a front-line Phase III study in unresectable hepatocellular carcinoma (HCC) Liver cancer is the 6th most common cancer and in 2020 was the third leading cause of cancer deaths worldwide Results to be presented at the 2021 Gastrointestinal Cancers Symposium organi

The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infection Roche will be able to ramp up to a double-digit million number of tests per month, by early 2021 The test is the latest addition to Roches comprehensive COVID-19 portfolio and can help in the management of patie

Moderna's vaccine triggers an antibody response to the SARS-CoV-2 spike protein The Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine trial participants and could help to establish correlation to protection from COVID-19 Emergency Use Authorisation by the US FDA for the Elecsys Ab test was granted on 25 Nov, 2020 - Basel, 9 December 2020 - Roche today announced a partnership with Moderna Inc.

Elecsys Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike protein The spike protein is the target of many COVID-19 vaccines in development This test may help identify recovering patients who could potentially be serum and plasma donors for developing treatments for COVID-19 - Basel, 2 December 2020 - Roche today

FDA BDD acknowledges the importance of GDF-15 testing in identifying eligible cachexic patients with solid tumours to be treated with Pfizer's investigational drug PF-06946860 Unintentional weight loss (cachexia) is a highly prevalent complication of cancer, affecting more than half of all cancer patients worldwide, potentially leading to signif

UPath HER2 (4B5) image analysis and uPath Dual ISH image analysis aid pathologists in providing faster, more accurate patient diagnoses in breast cancer In combination with the VENTANA DP 200 slide scanner and Roche uPath enterprise software, the new algorithms provide innovative digital pathology solutions to advance personalised healthcare  Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year.

People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) Tecentriq monotherapy, compared with those without ctDNA The goal of current treatment in people with MIUC is to provide early intervention to reduce the risk of the disea

Latest data to be presented at ASH 2020 includes results in non-Hodgkin lymphoma and heavily pre-treated multiple myeloma Portfolio includes two CD20xCD3 bispecifics, mosunetuzumab and glofitamab, and first-of-its-kind FcRH5xCD3 bispecific antibody, cevostamab, building on Roche's legacy of more than 20 years in antibody development Roche today

Basel, 2 December 2020 - Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto(TM) (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic